# US 2019/0293664 A1 · Method for indirectly measuring lead ion concentration in blood

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0293664 A1
- Document ID: US20190293664A1
- Status: Published application
- Kind: A1
- Application number: 15/928,573
- Filed: 2018-03-22
- Published: 2019-09-26
- Earliest claimed: 2018-03-22
- Assignees: Kaohsiung Medical University
- Applicants: Kaohsiung Medical University
- Inventors: Yu-Chang TYAN; Hung-Yi CHUANG; Ming-Hui YANG
- Web page: https://patentgrep.com/patent/US20190293664A1

## CPC

- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 33/72: involving blood pigments, e.g. haemoglobin, bilirubin {or other porphyrins; involving occult blood}
- G01N 33/721: {Haemoglobin}
- G01N 33/84: involving inorganic compounds or pH
- C01G 21/00: Compounds of lead
- C12N 9/6427: {Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)}
- C12Y 304/21004: Trypsin (3.4.21.4)
- G01N 30/7233: {interfaced to liquid or supercritical fluid chromatograph (interfaces in general for introducing or extracting samples to be analysed with specially adapted mass spectrometer, see H01J49/04)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C01G: COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F (metal hydrides {monoborane, diborane or addition complexes thereof} C01B6/00; salts of oxyacids of halogens C01B11/00; peroxides, salts or peroxyacids C01B15/00; thiosulfates, dithionites, polythionates C01B17/64; compounds containing selenium, or tellurium C01B19/00; binary compounds of nitrogen with metals C01B21/06; azides C01B21/08; {compounds containing nitrogen, other non-metals and metal C01B21/082}; metal amides C01B21/092; nitrites C01B21/50; {compounds of noble gases C01B23/0005}; phosphides C01B25/08; salts of oxyacids of phosphorus C01B25/16; carbides C01B32/90; compounds containing silicon C01B33/00; compounds containing boron C01B35/00; compounds having molecular sieve properties but not having base-exchange properties C01B37/00; compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites, C01B39/00; cyanides C01C3/08; salts of cyanamide C01C3/16; thiocyanates C01C3/20)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A method for measuring blood lead ion concentration comprising the steps of: providing a blood sample; analyzing the blood sample by using a mass spectrometry to obtain a spectrum; calculating an intensity area of a characteristic peak at mass-to-charge ratio (m/z)=1088.16±0.05 in the spectrum; and calculating a lead ion concentration (μg/dL) in the blood sample using the formula of y=0.875x+11.5, wherein y indicates the intensity area, and x indicates the lead ion concentration in the blood sample.

## Claims

### Claim 1

A method for measuring blood lead ion concentration comprising:
providing a blood sample;
analyzing the blood sample by using a mass spectrometry to obtain a spectrum;
calculating an intensity area of a characteristic peak at mass-to-charge ratio (m/z)=1088.16±0.05 in the spectrum; and
calculating a lead ion concentration (m/dL) in the blood sample using formula: y=0.875x+11.5,
wherein y indicates the intensity area, and x indicates the lead ion concentration in the blood sample.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the blood sample is a whole blood sample or a red blood cell sample.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the blood sample is treated with digestive enzyme.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the digestive enzyme is trypsin.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the mass spectrometry is a liquid chromatography mass spectrometry (LC-MS) or a matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS).

### Claim 6 (depends on 1)

The method according to claim 1, wherein the intensity area is calculated by integration.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the intensity value of the characteristic peak is a signal intensity value presented by an amino acid fragment of SEQ ID NO:1.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the amino acid fragment is derived from hemoglobin.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the lead ion is a divalent lead ion, a trivalent lead ion, or a combination thereof.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the lead ion concentration in the blood sample corresponds to the lead ion concentration measured by inductively coupled plasma-mass spectrometry (ICP-MS) in the same blood sample.
